“…The accumulated data from survivin studies on human cancers suggest that survivin expression in cancer is associated with cancer progression, poor prognosis, drug resistance, and shorter patient survival (Li, 2003). In vitro and in vivo studies targeting survivin with antisense oligonucleotides (Li et al, 1999;Chen et al, 2000;Olie et al, 2000;Xia et al, 2002), dominant-negative mutants (Li et al, , 1999Grossman et al, 1999a, b;O'Connor et al, 2000;Mesri et al, 2001), ribozymes (Pennati et al, 2002;Choi et al, 2003), triplex DNA-formation (Shen et al, 2003) and RNA interference (Ling and Li, 2004) have shown induction of apoptosis, reduction of tumorgrowth potential, and sensitization to chemotherapeutic drugs and other therapeutic approaches . These studies indicate that survivin is an excellent novel target for cancer therapeutics.…”